Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Moleculin Biotech Q3 2026 Results: Net Loss of $6.49M, Loss Narrows

Moleculin Biotech reported a net loss of $27.0 million for the nine months ended September 30, 2026, compared to a $49.1 million loss in the prior year period. The company ended the quarter with $7.3 million in cash and cash equivalents, supported by $20.3 million in net cash provided by financing activities during the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-6.5-25.4
EPS (diluted, $ a share)$-9.59$-340.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MBRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Moleculin Biotech, Inc.: key numbers

Share price
$7.14Close, Nov 16
Market cap
$7.58M
Shares outstanding
1.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Moleculin Biotech, Inc.

All →
7:31 AM ET 8-K
Financial Results

Moleculin Biotech Financial Results

Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.

“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin
8:38 AM ET 8-K
Business Update

Moleculin Biotech Business Update

Moleculin Biotech announced the grant of Australian Patent No. 2020303572, which covers the preparation of preliposomal Annamycin lyophilizate. The patent was granted jointly to Moleculin and The Board of Regents of The University of Texas System, strengthening the company's international intellectual property portfolio for its lead drug candidate, Annamycin.

Counterparty
The Board of Regents of The University of Texas System
4:09 PM ET 8-K
Clinical Trial Data

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced new preclinical data showing its lead drug candidate, Annamycin, combined with PD-1 immune checkpoint blockade, significantly extended survival in pancreatic cancer models. The data, presented at the Marie Skłodowska-Curie Symposium, suggests Annamycin can turn immunologically 'cold' tumors 'hot' by increasing T cell infiltration, potentially enabling combination therapies with existing immunotherapies.

Counterparty
The University of Texas MD Anderson Cancer Center
4:02 PM ET 8-K
Clinical Trial Data

Moleculin Biotech Clinical Trial Data

Moleculin Biotech announced that interim data from its pivotal Phase 2/3 trial (MB-108) of Annamycin for relapsed or refractory AML will be presented at the 2026 ASH Annual Meeting. The data showed complete remission rates of 43% and 36% in the treatment arms compared to 12% for placebo, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended the study continue without amendment.

8:50 AM ET 8-K
Business Update

Moleculin Biotech Business Update

Moleculin Biotech has completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (R/R AML). The company remains on track to report comprehensive data from the 90-patient Part A population in the first quarter of 2027, which will inform dose selection for Part B of the trial.

7:00 AM ET 8-K
Reverse Stock Split

Moleculin Biotech Reverse Stock Split

Moleculin Biotech announced a 1-for-20 reverse stock split of its common stock, effective October 20, 2026. The split will reduce the number of outstanding shares from approximately 20.91 million to approximately 1.05 million to satisfy Nasdaq listing requirements. The company's common stock will continue to trade under the ticker 'MBRX' with a new CUSIP number.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.